<i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients

Abstract

Tumor-associated genes (PRAME, WT1 and XIAP) expression study is conducted in 34 patients with multiple myeloma (MM) in disease onset and after chemotherapy (VAD, 20 pts) and proteosom inhibitor therapy (10 pts). PRAME, WT1 и XIAP gene expression in bone marrow cells detected by polymerase chain reaction (PCR) method. PRAME gene expression in 62% primary patients was revealed, thus expression median was 0.3% that almost in 100 times greater than in bone marrow donors (0.0035%). WT1 gene expression in 20% patients was detected, and it was determined only in PRAMEpositive patients. At diagnosis XIAP gene expression was revealed in all MM patients, thus expression median was more 10 times greater than in the control groups (28% versus 2%). In patients with PRAME hyperexpression partial response was achieved only in 25% of cases, while in patients with low or absence of PRAME expression VAD therapy was effective in 75% of cases (р=0,06). After bortezomib treatment XIAP gene expression level was significantly decreased with complete and partial remission achievement: from 11-325% (median – 66%) to 1-123% (median – 20%). In cases of tumor resistance to bortezomib treatment XIAP expression increased from 16-127% (median – 36%) to 22-528% (median – 121%).

Keywords

• multiple myeloma
• tumor-associated genes <i>prame
• wt1
• xiap</i>
• chemotherapy
• proteosom inhibitors
• bortezomib